CANC
Tema Oncology ETF
CANC is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations.
Global
EQUITY
Active
MANAGEMENT STYLE
$ 193.2 M
ASSETS UNDER MGMT
75 bp
EXPENSES
Fund Basics
| Inception date | Aug 15, 2023 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| REVOLUTION MEDICINES, INC. | 6.0 % |
| COGENT BIOSCIENCES INC | 4.9 % |
| ELI LILLY & CO | 4.9 % |
| NOVARTIS AG | 4.0 % |
| ROCHE HOLDINGS LTD-SPONS ADR | 3.7 % |
| MERCK & CO. INC. | 3.4 % |
| JOHNSON & JOHNSON | 3.3 % |
| BRISTOL-MYERS SQUIBB CO | 3.2 % |
| IMMUNOME, INC. | 3.2 % |
| ABBVIE INC | 3.2 % |
Constituent Breakdown
| Number of holdings | 55 |
| Herfindahl-Hirschman Index | 277 |
| Wgt avg mkt cap (mns) | $147,137 |
| Large cap (>$10bn) | 51.7% |
| Mid cap ($2-10bn) | 24.4% |
| Small cap (<$2bn) | 20.8% |
| Developed mkts. | 94.1% |
| Emerging mkts. | 3.4% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 76.6 % |
 |
SWITZERLAND | 7.7 % |
 |
CHINA | 3.7 % |
 |
BRITAIN | 3.5 % |
 |
DENMARK | 2.6 % |
 |
CANADA | 1.4 % |
 |
GERMANY | 0.8 % |
 |
JAPAN | 0.6 % |
Historical Performance
Standardized Performance (as of 06/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 18.8% | 66.8% | 23.6% | -- | -- | -- | -- | 148.1% |
| Dividend Yield | 0.0% | 0.1% | 1.7% | -- | -- | -- | -- | 2.9% |
| Total Returns | 18.8% | 66.9% | 25.4% | -- | -- | -- | -- | 151.0% | Ann. Volatility | 24.5% | 22.7% | 24.3% | -- | -- | -- | -- | 422.4% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.75 | 17% |
| MSCI EAFE | 0.73 | 25% |
| MSCI Emg Mkts | 0.34 | 11% |
Liquidity Measures
| Avg. volume (000) | 41 |
| ADV traded (mns) | $2 |
| Turnover | 0.9% |
| Avg. Bid/Ask (% of price) | 0.67% |
Technical Indicators
| 30d moving avg. (EMA) | $39.61 |
| Relative strength (RSI) | 61 |
| MACD/Signal | 1.23/1.01 |
| Bollinger Bands (Upper/Lower) | $43.65/$35.86 |
| Short interest (% of AUM) | 1.2% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. CANC |
Expenses vs. CANC |
ALTAR Score™ vs. CANC |
|---|---|---|---|---|
| HRTS | Tema Heart & Health ETF | 36.3% | 0 bp | +5.0% |
| IXJ | iShares Global Healthcare ETF | 27.4% | -33 bp | +8.6% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 26.8% | -15 bp | +8.8% |
| AGNG | Global X Aging Population ETF | 26.1% | -25 bp | +7.2% |
| MEDX | Horizon Kinetics Medical ETF | 24.6% | +10 bp | +3.3% |
| XBI | State Street SPDR S&P Biotech ETF | 24.1% | -40 bp | +1.7% |
| VHT | Vanguard Health Care ETF | 23.4% | -66 bp | +7.2% |
| IYH | iShares U.S. Healthcare ETF | 23.3% | -35 bp | +7.9% |
| FHLC | Fidelity MSCI Health Care Index ETF | 23.2% | -67 bp | +8.1% |
| WDNA | WisdomTree BioRevolution Fund | 23.1% | -30 bp | -0.7% |
Risk and Returns: CANC vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 7/16/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-1.9%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 733 funds in the Global Equity category with an average
ALTAR Score™ of 4.4% and a standard deviation
of 2.6%. CANC's ALTAR Score™ is approximately -2.4 standard
deviations above the category average. This places CANC in the 1st percentile
among funds in the category.
Sell-Side Consensus
$48
PRICE TARGET
+18.5%
UPSIDE
Bid/Ask Spreads
67 bp
AVG SPREAD
27 —
150 bp
RANGE